66358-23-4 Usage
General Description
Imidazo[1,2-a]pyridin-5-ylamine, also known as IPyA, is an organic compound commonly used in pharmaceutical research and drug development. It has a fused imidazole and pyridine ring structure, making it a versatile building block in organic synthesis. IPyA has shown potential biological activity as it is a potent inhibitor of the enzyme adenosine 5'-monophosphate-activated protein kinase (AMPK), which is involved in cellular energy homeostasis. This makes it a promising candidate for the development of new drugs targeting metabolic disorders and cancer. Additionally, its chemical structure can be modified to create new derivatives with improved properties for specific applications in medicinal chemistry. Overall, Imidazo[1,2-a]pyridin-5-ylamine has significant potential as a valuable chemical compound in various biomedical and pharmaceutical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 66358-23-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,6,3,5 and 8 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 66358-23:
(7*6)+(6*6)+(5*3)+(4*5)+(3*8)+(2*2)+(1*3)=144
144 % 10 = 4
So 66358-23-4 is a valid CAS Registry Number.
InChI:InChI=1/C7H7N3/c8-6-2-1-3-7-9-4-5-10(6)7/h1-5H,8H2
66358-23-4Relevant articles and documents
HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE
-
Page/Page column 28, (2010/07/02)
Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).
NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS
-
Page/Page column 153-154, (2010/02/11)
There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A'): wherein X is a carbon and X is an oxygen, a sulfur or - NR -,or formula (A"): wherein X is a nitrogen and R is an optionally substituted hydrocarbyl, Ris an amino substituted by two optionally substituted hydrocarbyl groups, Ris an phenyl, Y is CR or a nitrogen, Y is CRor a nitrogen and Yis CRor a nitrogen, provided that one or less of Y, Y, and Y is nitrogen, W is a bond, -(CH2)n-, and Z is a bond, -NR -,etc.; or a salt thereof or a prodrug thereof.
